The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.

doi:10.1172/jci.insight.147617

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.

JCI insight - 8 Jun 2021

Janiszewska Michalina, Stein Shayna, Metzger Filho Otto, Eng Jennifer, Kingston Natalie L, Harper Nicholas W, Rye Inga H, Alečković Maša, Trinh Anne, Murphy Katherine C, Marangoni Elisabetta, Cristea Simona, Oakes Benjamin, Winer Eric P, Krop Ian E, Russnes Hege G, Spellman Paul T, Bucher Elmar, Hu Zhi, Chin Koei, Gray Joe W, Michor Franziska, Polyak Kornelia

Abstract excerpt

Despite the availability of multiple human epidermal growth factor receptor 2-targeted (HER2-targeted) treatments, therapeutic resistance in HER2+ breast cancer remains a clinical challenge. Intratumor heterogeneity for HER2 and resistance-conferring mutations in the PIK3CA gene (encoding PI3K catalytic subunit α) have been investigated in response and resistance to HER2-targeting agents, while the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Class I Phosphatidylinositol 3-Kinases

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Neoplasm Transplantation

Share to Trastuzumab

Share to Tumor Microenvironment

Share to Vesicular Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 33886505
DOI: 10.1172/jci.insight.147617
PMCID: PMC8262355

Genes

PIK3CA
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.PMID 33886505Read ↗

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumorsSemantic proximity Read ↗

Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumorsSemantic proximity Read ↗

The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneitySemantic proximity Read ↗

Breast Cancer Heterogeneity and Response to Novel TherapeuticsSemantic proximity Read ↗

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.Semantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

Tumor Heterogeneity in Breast CancerSemantic proximity Read ↗

The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsivenessSemantic proximity Read ↗

Intratumoral Heterogeneity: From Diversity Comes ResistanceSemantic proximity Read ↗

Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer.Semantic proximity Read ↗

High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast CancerSemantic proximity Read ↗

Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and GuidelinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.